Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2020: (Do not round intermediate calculations. Round final answers to nearest whole dollor.) Date of Deprec. Residual Accum. Recoverable Asset Purchase Method Cost Value Useful life Deprec Amount Equipment May 1/15 Units $ 47,000 $ 3, 110 7,700 units $ 26,790 $ 6,110 Furniture Jun. 28/15 DOB 19,000 2,700 15,599 3,650 Land Ape 5/15 N/A 92,000 NA N/A WA 105, 10 Office building Apr. 5/15 SL 91.000 23,389 15 yes 29.300 59.500 Warehouse Apr. 5/15 SU 65,500 17,800 19,938 52,100 8 yrs 20 yrs "DDB = Double-declining balance: SL - Straight-line: Units Units-of-production: N/A - Not applicable Required: 1. Record any impairment losses at December 31, 2020. Assume Kane Biotech has recorded no impairment losses in previous years. View transaction list Journal entry worksheet Record impairment loss on PPE, if any. Note: Enter debits before credits. Date General Journal Debit Credit Dec 31, 2020 Record entry Clear entry View general Journal 2. Record depreciation for each asset at December 31, 2021. Assume that there was no change in the residual values or useful lives regardless of any impairment losses that might have occurred. The equipment produced 2,150 units during 2021 View transaction list Journal entry worksheet